leisure time -WSS

leisure time

author：focus 2025-09-27 23:01:06 - browse：92

Are there still too many biotech companies? How do you know when you’re in a bubble? And is there a wrong way to pronounce “TIGIT”?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Josh Schimmer and Eric Schmidt, two longtime analysts teaming up at Cantor Fitzgerald, join us for a back-to-school conversation as biotech enters the busy back third of 2023. We also discuss the latest news in the life sciences, including some scientific evolution at Biogen, new leadership at Illumina, and the future of CRISPR medicine.

For more on what we cover, here’s the news from Biogen; here’s more on Illumina; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： FDA's Pazdur wants cancer trials to range beyond China alone

WSS

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Some top drug companies are starting to take action on climate

ASCO: AstraZeneca says CAR

ASCO: Palliative care found as helpful given virtually as in person

HIV drugs protect against transmission, even in unprotected sex

hotspot

leisure time

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

See how much Covid

In age of alternative facts, a scholarly course on calling out crap

Some top drug companies are starting to take action on climate

Bright Health sells Medicare Advantage business to Molina

IVG is promising — but it won’t replace IVF quite yet

Apple is now the first public company to be valued at $3 trillion

The biotech scorecard for Q4: 16 stock

Bright Health sells Medicare Advantage business to Molina

Stop Congress from blocking public access to science

hotspot

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

What we owe ALS patients — and why one company fell short

FDA's Pazdur wants cancer trials to range beyond China alone

Some top drug companies are starting to take action on climate

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

RSV injection headlines need to be accurate for good uptake

Wikipedia

entertainment

explore

explore